TAG Calls for Universal Access to Innovative HCV Testing to End the Disease by 2030
July 25, 2024 — This World Hepatitis Day, July 28, we are better positioned than ever to end hepatitis C Virus (HCV) as a pandemic.

Three New Members Elected to TAG’s Board of Directors
July 25, 2024 — Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, “TAG is reinvigorating its Board in alignment with our vision, mission, and values.

TAG Calls on Danaher to Drop the Prices of GeneXpert Tests and Make the Cost Audit Public
June 26, 2024 — Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions
June 20, 2024 — Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.

Treatment Action Group Calls on NY City Council to Override and Mayor Adams to Reverse Egregious Cuts to New York City HIV Funding
May 22, 2024 — In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New…

Treatment Action Group Welcomes Two New Board Members
May 8, 2024 — Treatment Action Group (TAG) is pleased to announce that two new members have been elected to the Board of Directors, Ama Burnham and Dr. Stefan V. Goldberg.

Treatment Action Group Is Organizational Sponsor of SYNChronicity 2024
April 2, 2024 — Treatment Action Group (TAG) is proud to be one of the organizational sponsors of SYNChronicity 2024 (SYNC 2024). This annual national conference for HIV, HCV, STIs, harm reduction, and LGBTQ health will be held in Arlington, Virginia, from May 29 – 31; more than 1500 attendees are expected to participate.

Mid-Campaign Report Highlights What’s Needed to Win Better, Shorter TB Treatments for All by End of 2024
March 22, 2024 — Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6×24 Campaign coalition has found.

2024 CROI Tuberculosis Research Round Up
March 14, 2024 — Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). The highlights presented here cover the results of several phase II TB prevention and treatment trials.

TAG Announces New Board Leadership
February 14, 2024 — Treatment Action Group (TAG), the New-York-City-based activist research and policy think tank working to end the epidemics of HIV, TB, and hepatitis C, made leadership changes at its annual Board of Directors meeting on February 10, 2024.